Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisatracurium
Drug ID BADD_D02422
Description Cisatracurium is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.
Indications and Usage For inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.
Marketing Status approved
ATC Code M03AC11
DrugBank ID DB00565
KEGG ID D00759
MeSH ID C101584
PubChem ID 62887
TTD Drug ID D08ALK
NDC Product Code Not Available
UNII QX62KLI41N
Synonyms cisatracurium | cisatracurium besylate | cisatracurium besilate | Nimbex | 51W89
Chemical Information
Molecular Formula C53H72N2O12+2
CAS Registry Number 96946-41-7
SMILES C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CC C5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction10.01.07.001; 24.06.03.0060.000199%
Anaphylactic shock10.01.07.002; 24.06.02.0040.000085%-
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.000057%-
Apnoea22.02.01.0010.000370%
Bradycardia02.03.02.0020.000171%-
Condition aggravated08.01.03.0040.000057%-
Drug ineffective08.06.01.0060.000666%-
Drug interaction08.06.03.0010.000057%-
Hyperthermia malignant08.05.01.0020.000142%-
Hypotension24.06.03.0020.000154%
Pyrexia08.05.02.0030.000057%
Respiratory acidosis14.01.04.002; 22.02.02.0040.000057%-
Tachyphylaxis08.06.01.028; 10.02.01.0500.000194%-
Therapeutic response decreased08.06.01.0160.000085%-
Therapeutic product effect decreased08.06.01.0500.000125%-
Therapeutic product effect incomplete08.06.01.0520.000194%-
Therapeutic product effect prolonged08.06.01.0540.000114%-
The 1th Page    1    Total 1 Pages